Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP407869.RATiR9AbztCiC8L1gQHmMstCEOGMcPrUxTezkSjk0-yTA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP407869.RATiR9AbztCiC8L1gQHmMstCEOGMcPrUxTezkSjk0-yTA130_assertion type Assertion NP407869.RATiR9AbztCiC8L1gQHmMstCEOGMcPrUxTezkSjk0-yTA130_head.
- NP407869.RATiR9AbztCiC8L1gQHmMstCEOGMcPrUxTezkSjk0-yTA130_assertion description "[Together these data suggest quizartinib, with its unique combination of selectivity and potent/sustained inhibition of FLT3, may provide a safe and effective treatment against FLT3-driven leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP407869.RATiR9AbztCiC8L1gQHmMstCEOGMcPrUxTezkSjk0-yTA130_provenance.
- NP407869.RATiR9AbztCiC8L1gQHmMstCEOGMcPrUxTezkSjk0-yTA130_assertion evidence source_evidence_literature NP407869.RATiR9AbztCiC8L1gQHmMstCEOGMcPrUxTezkSjk0-yTA130_provenance.
- NP407869.RATiR9AbztCiC8L1gQHmMstCEOGMcPrUxTezkSjk0-yTA130_assertion SIO_000772 23412931 NP407869.RATiR9AbztCiC8L1gQHmMstCEOGMcPrUxTezkSjk0-yTA130_provenance.
- NP407869.RATiR9AbztCiC8L1gQHmMstCEOGMcPrUxTezkSjk0-yTA130_assertion wasDerivedFrom befree-20150227 NP407869.RATiR9AbztCiC8L1gQHmMstCEOGMcPrUxTezkSjk0-yTA130_provenance.
- NP407869.RATiR9AbztCiC8L1gQHmMstCEOGMcPrUxTezkSjk0-yTA130_assertion wasGeneratedBy ECO_0000203 NP407869.RATiR9AbztCiC8L1gQHmMstCEOGMcPrUxTezkSjk0-yTA130_provenance.